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Objectives: The German market access system for drugs have been changed 
significantly in the last years, by introducing a similar focus on benefit assessment 
as in the French system. The research question remains whether they produce 
consistent results in terms of additional benefit (AB) for pharmaceuticals which 
have passed the assessment in both systems. MethOds: The G-BA and IQWiG as 
well as the Transparency Commission (TC) databases were searched systematically 
to identify those products, which have been processed in both systems between 
Jan 2011 and Dec 2013. For further comparison a data grid consisting of 26 items 
for evaluation has been developed including study comparator, primary clinical 
endpoints, health related quality of life inclusion. Results: Overall, 140 new 
therapies have been assessed in France by TC, and 80 in Germany by the G-BA. 
According to inclusion criteria, 44 products could be identified which have passed 
through both systems including 7 orphan drugs. Thirteen products (30%) had no 
AB granted by both Agencies, whereas 9 (20%) were in both cases granted with a 
minor AB, (assuming that “minor” values are equivalent between the two systems), 
amounting to 22/44 cases with a similar resolution. Five cases (11%) showed a 
discrepancy in added benefit, all times TC = no and G-BA = yes. However, varying 
magnitudes appeared to be the greatest difference (n = 17 (39%) remaining drugs), 
conditioned by lacking concordance of both scale grade systems. cOnclusiOns: 
Decisions of the agencies in both countries show partial heterogeneity in driving 
criteria like benefit levels (ASMR and AB). Although the evidence package for initial 
assessment in both countries is largely similar, preliminary results suggest their 
contextualization and scales are different. Further analysis based on results of 
the grid is needed to better assess criteria leading to different benefit levels and 
their reimbursement impact.
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Objectives: In the Netherlands, manufacturers need to apply for reimbursement 
of outpatient drugs on either list 1A (no added benefit) or 1B (added benefit). For 
expensive drugs, hospitals can receive additional reimbursement if the drug is 
included on the expensive drug list (EDL). Pharmacoeconomic evidence is only 
required for list 1B and EDL evaluations. The National Health Care Institute (NZi) 
evaluates submissions and makes (provisional) reimbursement recommenda-
tions to the Dutch government. The aim of this study was to identify explanatory 
variables for the recommendation by NZi. MethOds: A database of published 
evaluations from February-2006 to March-2014 was created, consisting of the 
final reimbursement recommendation and a range of corresponding explanatory 
variables such as the therapeutic indication, clinical and economic characteris-
tics. Univariate analyses were performed to assess the impact of the individual 
explanatory variables on the recommendation by means of odds ratios. Results: 
In total 262 applications were included; the number of positive recommenda-
tions by NZi were 121/122 (99%) for 1A, 77/107 (72%) for 1B and 19/28 (68%) for 
EDL. Pharmacoeconomic analysis was reported in 36/107 (34%) 1B evaluations, 
of which 27 (75%) were recommended. For the EDL category, pharmacoeconomic 
analysis was reported in 20/28 (71%) evaluations, out of which 17 (85%) received a 
positive recommendation. Univariate analyses for the 1B subgroup showed that 
NZi recommendations were significantly (α = 0.05) influenced by clinical trials with 
life-saving primary endpoint (positive), non-inferior trial outcomes compared to 
placebo (negative) and budget impact below € 2,500,000 (positive). Whereas, the 
univariate analyses on EDL evaluations demonstrated that ATC-code L (antineo-
plastic and immunomodulating agents), clinical trials with life-saving primary 
endpoint and reporting of economic analysis outcomes had a significant and posi-
tive impact on the final NZi recommendation. cOnclusiOns: These univariate 
analyses demonstrated that for 1B and EDL evaluations indication, clinical and 
economic factors impact the NZi reimbursement recommendations.
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Objectives: When assessing trends in NICE HTA decisions it would be useful 
to ascertain their implications on access for groups of technologies. A specific 
issue is to understand the degree of access associated with ‘optimised’ decisions, 
where usage has been restricted to a subgroup of patients relative to the scope of 
the appraisal. Using a previously developed method, we calculate the degree of 
recommended access for medicines and assess trends between 2008 and 2013 by 
therapeutic area and over time. MethOds: In a previously published paper we 
developed a measure, m, to assess access associated with NICE technology opti-
mised appraisal decisions. This was defined as m=(p/P)x100, where m is a measure 
of the level of patient access (0 equals no access, 100 full access), P is the set of 
patients considered in the guidance as potential candidates for treatment (given 
the scope of appraisal and license), and p is the number of patients for whom 
NICE did recommend. Applying measure m to NICE HTA decisions for medicines 
between January 2008 and December 2013 we assess trends by therapeutic area 
and over time. In this paper, to understand trends, we extend the analysis to 
include recommended and not recommended decisions. We assume a recom-
mended decision scores 100 using measure m, a not recommended decision 0, and 
optimised decisions, where not possible to determine m, a score of 50. Results: 
For 201 decisions between 2008 and 2013, on average, m was equal to 52, ranging 
from 37 in 2008 to 57 in 2011. At therapy level, m scored between 38 for cancer 
medicines to 100 for Hepatitis C treatments. cOnclusiOns: The results for this 
period suggest around half of patients have been recommended by NICE to receive 
treatment, relative to scope of appraisal and license. These considerations address 
access not implementation issues.
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Objectives: There are a number of common elements considered good practice 
in Health Technology Assessment (HTA) that have been published by organizations 
representing the field. These components include: clear processes and decision-
making, including scope for pragmatic approaches and appeal; transparency in 
methodology, value judgments and decisions; and a facility for stakeholder involve-
ment. The objective of this study was to compare international HTA systems to 
rank their performance against the ideal components of HTA. Information was 
also collected on emerging topics such as combined regulatory-payer scientific 
advice, coverage with evidence, evaluation of drug-diagnostic pairs and disinvest-
ment. MethOds: A survey was designed to collect information on the HTA sys-
tems in the United Kingdom (UK), France, Germany, Italy, The Netherlands, Sweden, 
Central Eastern Europe, Canada, Australia, New Zealand (NZ), Korea and Taiwan. 
Questions were grouped under the topics: process, methods, data, societal input 
and transparency. The survey was completed by Roche affiliates with first-hand 
experience working with the HTA system in their country. Results: The majority 
of countries give consideration to rare diseases and low budget impact with leniency 
in decision making and/or process. Transparency in decision-making is lacking in 
many of the countries surveyed. Whilst consumer members sit on decision-making 
committees in several countries, only the UK involves a group of citizens in setting 
the decision making criteria applied by the committee. Combined regulatory-payer 
scientific advice is only available in European countries. Australia is the only country 
to evaluate drug-diagnostic pairings for both costs and outcomes. Only the UK and 
NZ have routine disinvestment reviews. cOnclusiOns: Each country is perform-
ing well in some elements of their HTA system, but none met all the requirements 
of an ideal system. HTA systems can learn from the experiences in other countries 
when considering improvements to processes and efficiency.
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Objectives: Regulatory Scientific Advice (SA) provided by EMA, FDA, MHRA and other 
agencies is highly demanded by manufacturers but health technology assessment 
(HTA) scientific advice is still far from becoming a routine step in the product develop-
ment cycle. NICE has been running an advisory service for 5.5 years. MethOds: This 
work presents analysis of requests to the programme: types of advice projects, num-
ber and type of requests per company, clinical indication, stage of clinical develop-
ment when the advice is sought, reason for seeking advice and current development 
and regulatory status of products. Results: Between 2009 and 2014 NICE conducted 
109 advisory projects (107 medicinal products and two diagnostic tests). 23 of these 
projects were done in parallel with regulatory agencies and/or other HTA bodies. 
78% of all requests were in the following four therapeutic areas: oncology, neurology, 
rheumatology and cardiology. Majority of products (61%) were in phase II of clinical 
development when advice was sought. At the time of this analysis, 71 products (66%) 
were still in development, 6 (5.5%) were subject of a review for a marketing authorisa-
tion (MA), 8 (7.5%) had received a MA, the authorisation was not granted to 2 products 
(2%) and the clinical development was discontinued in 20 cases (19%). Most products 
that received NICE scientific advice are yet to be referred to the technology appraisals 
programme. cOnclusiOns: Over the last few years, requests for scientific advice 
diversified into personalised medicines, regenerative medicines and products for rare 
and very rare diseases. Most HTA scientific advice requests continue to come from 
top 20 Pharma companies, however we are starting to see an increasing number of 
inquiries and project bookings from small-medium size companies.
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Objectives: Since October 2013, HAS is required to provide the inter-minis-
terial Economic Committee on Health Care Products (CEPS) with an economic 
evaluation on innovative medicines likely to have a significant budget impact 
on the national health insurance scheme. HAS economic evaluations are based 
on critical appraisals of cost-effectiveness analyses (CEA) submitted by manu-
facturers. Exploration of uncertainty around incremental cost-effectiveness 
ratio is critical to assess the robustness of CEA. Our objective was to assess how 
uncertainty exploration has been undertaken by manufacturers, using HAS 
guidelines on economic evaluation as an analytical framework. MethOds: 
Manufacturers’ submissions assessed by end of May 2014 (n= 13) were reviewed. 
Three sources of uncertainty were considered: uncertainty around model input 
parameters, uncertainty around model structure and methodological uncertainty. 
Tools to explore uncertainty included deterministic sensitivity analysis (DSA), prob-
abilistic sensitivity analysis (PSA), as well as overall compliance with HAS guide-
lines. Results: Model input parameters were the most frequently explored source 
of uncertainty. Both DSA and PSA were systematically used. However, reporting of 
DSA varied substantially across submissions, with frequent lack of justification of 
parameters ranges. Regarding PSA, the choice of distribution was not systemati-
cally justified and lacked consistency across similar parameters. Most submissions 
failed to consider parameters correlations. Exploration of uncertainty around model 
structure was rarely presented. Where applicable, alternative methods for extrapo-
